# A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy

> **NCT07669506** · PHASE3 · COMPLETED · sponsor: **Natureceuticals Sdn Bhd** · enrollment: 180 (actual)

## Conditions studied

- Breast Neoplasms
- Fatigue
- Quality of Life
- Chemotherapy, Adjuvant

## Interventions

- **DRUG:** Nuvastatic ™
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07669506
- **Lead sponsor:** Natureceuticals Sdn Bhd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-17
- **Primary completion:** 2026-04-25
- **Final completion:** 2026-06-15
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669506, "A Study to Evaluate the Efficacy and Safety of Orally Administered Extract of Orthosiphon Stamineus (NuvastaticTM-C5OSEW5050ESA) in Patient With Breast Cancer Undergoing Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*